|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
28
|
|
pubmed:dateCreated |
2005-9-29
|
|
pubmed:abstractText |
To determine the efficacy and safety of a newly developed concomitant administration of fludarabine and alemtuzumab (FluCam) in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:AulitzkyWalterW,
pubmed-author:BorchmannPeterP,
pubmed-author:ElterThomasT,
pubmed-author:EngertAndreasA,
pubmed-author:GramatzkiMartinM,
pubmed-author:HallekMichaelM,
pubmed-author:HasanIbrahimI,
pubmed-author:JensenMarkusM,
pubmed-author:JostingAndreasA,
pubmed-author:RechJürgenJ,
pubmed-author:ReiserMarcelM,
pubmed-author:SchinkötheTimoT,
pubmed-author:SchnellRolandR,
pubmed-author:SchulzHolgerH,
pubmed-author:StützerHartmutH,
pubmed-author:StaibPeterP,
pubmed-author:TrelleSvenS
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7024-31
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16145065-Adult,
pubmed-meshheading:16145065-Aged,
pubmed-meshheading:16145065-Aged, 80 and over,
pubmed-meshheading:16145065-Antibodies, Monoclonal,
pubmed-meshheading:16145065-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:16145065-Antibodies, Neoplasm,
pubmed-meshheading:16145065-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16145065-Drug Resistance, Neoplasm,
pubmed-meshheading:16145065-Female,
pubmed-meshheading:16145065-Humans,
pubmed-meshheading:16145065-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:16145065-Male,
pubmed-meshheading:16145065-Middle Aged,
pubmed-meshheading:16145065-Recurrence,
pubmed-meshheading:16145065-Treatment Outcome,
pubmed-meshheading:16145065-Vidarabine
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
|
|
pubmed:affiliation |
Department of Hematology and Oncology, University of Cologne, Cologne, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
